Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach.
One in eight men in the United States will develop prostate cancer as they get older. It’s the most common cancer in men in this country besides skin cancer. Worldwide, it is second only to lung cancer.